CPHL Pharmaceuticals: Major
Health Technology
64.76 +1.17%
Mkt Cap
14.6B
P/E (TTM)
18.50
EPS (TTM)
3.46
ROE (TTM)
7.28%
Div Yield
5.40%
Citi Pharma Ltd. (CPHL) Financial Statements, Ratios & Dividends
About
Citi Pharma Ltd. engages in the manufacturing and sale of pharmaceuticals, medical chemicals, and botanical products. Its products portfolio includes paracetamol, Penicillin/Amoxicillin, Levofloxacin, Cefixime/Cephalosporin, Ciprofloxacin, Cephradine, Norfloxacin, Aspirin, Ibuprofen, and Ascorbic Acid. The company was founded on October 8, 2012 and is headquartered in Lahore, Pakistan.
Financial Highlights
| FY2026 | FY2025 | ||
|---|---|---|---|
| Revenue | 14.08B | 13.15B | |
| Gross Profit | 2.36B | 1.92B | |
| Net Income | 790.33M | 892.04M | |
| EPS | 3.46 | 3.90 | |
| ROE | 7.28% | 10.81% | |
| ROA | 4.31% | 5.98% | |
| Gross Margin | 16.76% | 14.57% | |
| Net Margin | 5.61% | 6.78% | |
| Current Ratio | 1.25 | 1.30 | |
| DPS | — | 3.50 | |
| Free Cash Flow | -544.63M | -470.77M |
| FY2026 | FY2025 | ||
|---|---|---|---|
| Total Revenue | 14.08B | 13.15B | |
| Cost of Goods Sold | -11.72B | -11.24B | |
| Gross Profit | 2.36B | 1.92B | |
| SG&A Expenses | -512.69M | -384.67M | |
| Research & Development | -15.21M | -2.79M | |
| Depreciation | -206.04M | -168.09M | |
| Other Operating Expense | -27.25M | -27.05M | |
| Total Operating Expense | -12.26B | -11.65B | |
| Operating Income (EBIT) | 1.82B | 1.50B | |
| Interest Income | 91.65M | 181.89M | |
| Interest Expense | -382.90M | -323.63M | |
| Equity in Earnings | 0 | 0 | |
| Other Non-Operating Income | -9.72M | -8.68M | |
| Total Non-Operating Income | -474.91M | -150.42M | |
| Pre-Tax Income | 1.34B | 1.35B | |
| Income Tax | -554.18M | -462.47M | |
| Minority Interest | 0 | 0 | |
| Net Income | 790.33M | 892.04M | |
| EBITDA | 2.03B | 1.67B | |
| EPS (Basic) | 3.46 | 3.90 | |
| EPS (Diluted) | 3.46 | 3.90 | |
| Gross Margin | 16.76% | 14.57% | |
| Operating Margin | 12.93% | 11.44% | |
| EBITDA Margin | 14.39% | 12.72% | |
| Pre-Tax Margin | 9.55% | 10.30% | |
| Net Margin | 5.61% | 6.78% |
| FY2026 | FY2025 | ||
|---|---|---|---|
| Profitability | |||
| Return on Equity (ROE) | 7.28% | 10.81% | |
| Return on Assets (ROA) | 4.31% | 5.98% | |
| Return on Invested Capital | 7.21% | 10.77% | |
| Gross Margin | 16.76% | 14.57% | |
| Operating Margin | 12.93% | 11.44% | |
| EBITDA Margin | 14.39% | 12.72% | |
| Net Margin | 5.61% | 6.78% | |
| Pre-Tax Margin | 9.55% | 10.30% | |
| Liquidity | |||
| Current Ratio | 1.25 | 1.30 | |
| Quick Ratio | 0.71 | 0.76 | |
| Leverage | |||
| Debt / Equity | 0.29 | 0.27 | |
| Debt / Assets | 0.17 | 0.16 | |
| LT Debt / Equity | 0.01 | 0.01 | |
| LT Debt / Assets | 0.01 | 0.00 | |
| Net Debt | 2.75B | 1.36B | |
| Total Debt | 3.10B | 2.94B | |
| Efficiency | |||
| Asset Turnover | 0.77 | 0.88 | |
| Inventory Turnover | 3.04 | 3.12 | |
| Per Share | |||
| Book Value Per Share | 47.42 | 47.57 | |
| Tangible Book Per Share | 47.42 | 47.57 | |
| Cash Per Share | 1.52 | 6.95 | |
| Total Debt Per Share | 13.57 | 12.89 | |
| Working Capital Per Share | 7.75 | 9.48 | |
| Shares & Market | |||
| Total Shares Outstanding | 228,461,200 | 228,461,200 | |
| Market Cap | 17.79B | 19.18B | |
| Enterprise Value | 20.54B | 20.54B | |
| Employees | 633 | 627 | |
| Shareholders | 17,934 | 17,934 | |
| FY2026 | FY2025 | ||
|---|---|---|---|
| Dividends Per Share | — | 3.50 | |
| Dividend Yield | — | 4.17% | |
| Payout Ratio | — | 89.64% | |
| Total Dividends Paid | -800.24M | -739.82M |
| FY2026 | FY2025 | ||
|---|---|---|---|
| P/E Ratio | 22.51 | 21.51 | |
| P/B Ratio | 1.64 | 1.77 | |
| P/S Ratio | 1.26 | 1.46 | |
| P/CF Ratio | 109.78 | — | |
| EV/EBITDA | 10.14 | 12.28 | |
| Market Cap | 17.79B | 19.18B | |
| Enterprise Value | 20.54B | 20.54B |
| TTM | ||
|---|---|---|
| Income | ||
| Revenue | 14.08B | |
| Gross Profit | 2.47B | |
| Operating Income | 1.94B | |
| Net Income | 790.33M | |
| EBIT | 1.94B | |
| Free Cash Flow | -544.63M | |
| EPS (Basic) | 3.46 | |
| Margins | ||
| Gross Margin | 17.57% | |
| Operating Margin | 13.79% | |
| Net Margin | 5.61% | |
| Returns | ||
| Return on Equity (ROE) | 7.28% | |
| ROIC | 0.07% | |
| Coverage & Debt | ||
| Interest Coverage | 5.0x | |
| Dividend Coverage | 1.33 | |
| Debt / Revenue | 0.22 | |
| Valuation & Scores | ||
| P/E (TTM) | 18.50 | |
| Sloan Ratio | 6.96 | |
| Zmijewski Score | -2.22 | |
Computed Metrics (Latest Period)
| FY2026 | ||
|---|---|---|
| Extended Returns | ||
| Return on Common Equity | 7.28% | |
| Return on Tangible Equity | 7.28% | |
| Return on Tangible Assets | 4.31% | |
| Return on Total Capital | 13.12% | |
| ROCE | 16.22% | |
| Growth | ||
| EPS Diluted Growth | -0.11% | |
| Quality & Risk Scores | ||
| Piotroski F-Score | 4 | |
| Zmijewski Score | -2.22 | |
| Sloan Ratio | 6.96 | |
| Valuation (Computed) | ||
| Graham Number | 60.75 | |
| Tobin's Q Ratio | 0.97 | |
| Leverage & Coverage | ||
| Interest Coverage | 4.8x | |
| Total Debt / Capital | 0.22% | |
| Assets / Equity (Leverage) | 1.69 | |
| Net Debt / EBITDA | 1.36 | |
| Effective Interest Rate | 12.67% | |
| Debt / Revenue | 0.22 | |
| Efficiency (Computed) | ||
| Fixed Asset Turnover | 1.57 | |
| Receivables Turnover | 4.07 | |
| Dividends (Computed) | ||
| Dividend Coverage | 1.33 | |
| Share Buyback Ratio | 0.00 | |
| Per Employee | ||
| Revenue / Employee | 22.24M | |
| Net Income / Employee | 1.25M | |
| Oper. Income / Employee | 2.87M | |
| Total Assets / Employee | 28.85M | |
| Balance Sheet (Computed) | ||
| Tangible Assets | 18.26B | |
| Invested Capital | 10.98B | |
| Working Capital | 1.77B | |
| Book Value Per Share | 47.42 | |
| Earnings Schedule | ||